The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation (MA) for a new treatment for HR+ and HER2- breast cancer patients at high risk of recurrence, following results from a study led by Royal Marsden researchers.
The Royal Marsden has been supporting NHS England’s Targeted Lung Health Check programme which is piloting mobile lung health checks in areas of high lung cancer incidence, including Hillingdon and Sutton.
Artificial intelligence (AI) could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to a study led by researchers from The Royal Marsden NHS Foundation Trust in collaboration with The Institute of Cancer Research, London, and Imperial College London, which was supported by The Royal Marsden Cancer Charity.
A new type of immunotherapy making use of the immune system’s ‘natural killer cells’ could offer potential against a range of cancers that can evade current treatments, early results from a phase I trial suggest.
Bowel cancer is the fourth most common cancer in the UK, with nearly 43,000 new cases every year. For Bowel Cancer Awareness Month 2022, we are raising awareness of the symptoms to look out for.
A team working together across different areas of cancer research from The Royal Marsden and The Institute of Cancer Research has won one of the world’s most prestigious team science awards for work that has transformed treatment for many patients with breast cancer.
Mr Declan Cahill, Head of Urology at The Royal Marsden, recently passed a personal milestone by performing his 2,000th robotically assisted radical prostatectomy.
The ‘Man Van’, an innovative new outreach programme, has been launched today (Friday 18 March) to provide free health checks for men and boost early diagnosis of prostate and other urological cancers.
For Ovarian Cancer Awareness Month, Debbie shared her experience of being treated for ovarian cancer at The Royal Marsden.
The Royal Marsden NHS Foundation Trust has received a £3.1m funding boost as a National Institute for Health Research (NIHR) Clinical Research Facility (CRF) to help support our early-stage clinical research.